Daily Reporter

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More


Potential advance in HER+ patients with combination therapy

Non-chemotherapy-based combination therapies may play a possible role for the treatment of women with HER2-positive (HER2+) tumours, as by selectively targeting a specific group of patients, there is a greater opportunity to achieve control of…

Read More


Towards diagnosis of minimal residual disease

With technological advances increasing the sensitivity and specificity of testing, liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage…

Read More


RAS: a moving target

Ras oncogene means different things to different tumours in different tissues. Step away from RAS itself and we enter a universe of complex and diverse biological processes that Ras oncogene orchestrates. In my view, deep…

Read More